1,2-dihydro-4-[(3-fluoro-4-methylphenyl) methyl]-5-methyl-3H-pyrazole-3-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-dihydro-4-[(3-fluoro-4-methylphenyl) methyl]-5-methyl-3H-pyrazole-3-one
• 英文别名: 1,2-dihydro-4-[(3-fluoro-4-methylphenyl)-methyl]-5-methyl-3H-pyrazole-3-one；1,2-dihydro 4-[(3-fluoro-4-methyl phenyl)methyl]-5-methyl-3H-pyrazol-3-one；1,2-dihydro-4-[(3-fluoro-4-methylphenyl)methyl]-5-methyl-3H-pyrazol-3-one；4-[(3-Fluoro-4-methylphenyl)methyl]-1,2-dihydro-5-methyl-3H-pyrazol-3-one；4-[(3-fluoro-4-methylphenyl)methyl]-5-methyl-1,2-dihydropyrazol-3-one
• 化学式: C₁₂H₁₃FN₂O
• 分子量: 220.246
• InChiKey: IZIWAAJSYJYAOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-dihydro-4-[(3-fluoro-4-methylphenyl) methyl]-5-methyl-3H-pyrazole-3-one 、 2,3,4,6-四乙酰氧基-alpha-D-吡喃葡萄糖溴化物 在 silver carbonate 作用下， 生成 4'-[(3'-fluoro-4'-methylphenyl)methyl]-5'-methyl-1H-pyrazole-3'-O-(2,3,4,6-tetraacetyl)-β-D-glucopyranoside
  参考文献：
  名称：

  Pyrazole derivatives and diabetic medicine containing them

  摘要：

  本发明提供了以下式表示的吡唑-O-糖苷衍生物，用作糖尿病药物。

  公开号：

  US20040006025A1
• 作为产物：
  描述：

  2-(3-fluoro-4-methyl-benzyl)-3-oxo-butyric acid ethyl ester 在 肼 作用下， 以 甲苯 为溶剂， 生成 1,2-dihydro-4-[(3-fluoro-4-methylphenyl) methyl]-5-methyl-3H-pyrazole-3-one
  参考文献：
  名称：

  Pyrazole derivatives and diabetic medicine containing them

  摘要：

  本发明提供了以下式表示的吡唑-O-糖苷衍生物，用作糖尿病药物。

  公开号：

  US20040006025A1

文献信息

• Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
  申请人：Pfrengle Waldemar

  公开号：US20080020987A1

  公开（公告）日：2008-01-24

  The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R 1 to R 6 and R 7a , R 7b , R 7c are defined according to claim 1. Furthermore the present invention relates to processes for preparing educts and intermediates in the above processes and to intermediates as such.

  本发明涉及制备一般式I化合物的方法，其中基团R1至R6和R7a、R7b、R7c根据权利要求1中的定义。此外，本发明涉及制备上述方法中的底物和中间体的方法，以及中间体本身。
• Prophylactic and therapeutic agent of diabetes mellitus
  申请人：Maezono Katsumi

  公开号：US20050143424A1

  公开（公告）日：2005-06-30

  The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

  本发明提供了一种糖尿病的预防和治疗剂，包括肾脏葡萄糖重吸收抑制剂和降糖剂的组合。根据本发明，可以改善餐后、餐间和禁食期间的高血糖。更具体地，根据本发明，可以实现糖尿病的治疗效果，这是以往相关艺术中的降糖药物所未曾达到的。
• Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives
  申请人：Himmelsbach Frank

  公开号：US20070072813A1

  公开（公告）日：2007-03-29

  The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种预防或治疗代谢性疾病的方法，改善血糖控制，预防从糖耐量受损、胰岛素抵抗和/或代谢综合征进展到2型糖尿病，预防或治疗糖尿病并发症，减轻体重，预防或治疗胰岛β细胞退化，治疗高胰岛素血症和胰岛素抵抗以及1型糖尿病，方法是通过给需要的患者口服含有在权利要求1中定义的吡唑烷-O-糖苷或其前药或其药学上可接受的盐的药物组成物。
• Process for production of glucopyranosyloxypyrazole derivative
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US08022192B2

  公开（公告）日：2011-09-20

  The present invention relates to a method for preparing the glucopyranosyloxypyrazole derivatives which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications, obesity or the like. A glucopyranosyloxypyrazole derivative can be easily and efficiently prepared by allowing a benzylpyrazole derivative represented by the general formula: wherein R1, R2, R3, R4 and R5 may be the same or different, for example each of them is a hydrogen atom, a halogen atom or an alkyl, alkoxy, arylmethyloxy group or the like, R6 is an alkyl group, for example R7 is a hydrogen atom or an alkyl, alkoxy, arylmethyloxy group or the like, to react with a compound represented by the general formula: wherein as an example, PG1 is a pivaloyl group or the like, as an example, X1 is a bromine atom or the like, therefore the present invention is extremely useful as a method for preparing pharmaceutical compounds.

  本发明涉及一种制备葡萄糖吡唑基氧代吡唑衍生物的方法，该衍生物可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症、肥胖症等的药物。通过让一种由下式表示的苄基吡唑衍生物与下式表示的化合物反应，可以轻松高效地制备葡萄糖吡唑基氧代吡唑衍生物：其中R1、R2、R3、R4和R5可能相同或不同，例如它们中的每一个是氢原子、卤素原子或烷基、烷氧基、芳基甲氧基基团等，R6是烷基，例如R7是氢原子或烷基、烷氧基、芳基甲氧基基团等。例如，PG1是肉桂酰基等，X1是溴原子等。因此，本发明作为一种制备药物化合物的方法极为有用。
• PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE
  申请人：Pinnetti Sabine

  公开号：US20100317575A1

  公开（公告）日：2010-12-16

  The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  本发明涉及一种制药组合物，包括根据权利要求1所述的化合物（1）至（29）中选择的吡唑-O-葡萄糖苷衍生物，与至少一种第二治疗剂的组合物，该第二治疗剂适用于治疗或预防选择自1型糖尿病、2型糖尿病、糖耐量受损和高血糖等一个或多个疾病。此外，本发明还涉及预防或治疗代谢紊乱及相关疾病的方法。